EXHIBIT C

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Case 1:20-cv-00393-LMB-TCB Document 1402-2 Filed 07/21/22 Page 2 of 4 PageID# 34956431

429

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA

PHILIP MORRIS PRODCUTS S.A.,

Counterclaim Plaintiff,

v.

R.J. REYNOLDS VAPOR COMPANY,

Counterclaim Defendant.

VOLUME 2 - AFTERNOON SESSION TRANSCRIFT OF JURY TRIAL PROCEEDINGS BEFORE THE HONORABLE LEONIE M. BRINKEMA, UNITED STATES DISTRICT COURT JUDGE

APPEARANCES:

For the Plaintiffs:

Maximilian Antony Grant, Esq. Latham & Watkins LLP (DC) 555 11th Street, NW Suite 1000 Washington, DC 20004-1304 202-637-2200 Email: Max.grant@lw.com

Civil Action No. 1:20-cv-00393-LMB/TCB

June 9, 2022 2:05 p.m.

Clement Joseph Naples, Esq. Latham & Watkins, LLP 885 Third Avenue 25th Floor New York, NY 10022 212-906-1200 Email: Dement.naples@lw.com

Gregory K. Sobolski, Esq. Latham & Watkins, LLP 505 Montgomery Street Suite 2000 San Francisco, CA 94111-6538 202-637-2267 Email: Max.grant@lw.com

Scott L. Wallace, RDR, CRR Official Court Reporter

430

APPEARANCES: (Cont.)

For the Plaintiffs:

Thomas W. Yeh, Esq. Latham & Watkins LLP (CA) 355 South Grand Avenue Suite 100 Los Angeles, CA 90071-1560 213-891-8050 Email: Thomas.yeh@lw.com

Matthew John Moore, Esq. Latham & Watkins LLP (DC) 555 11th Street, NW Suite 1000 Washington, DC 20004-1304 202-637-2200 Email: Matthew.moore@lw.com

Dale Chang, Esq. Latham & Watkins LLP (CA) 355 South Grand Avenue Suite 100 Los Angeles, CA 90071-1560 213-891-8050 Email: Dale.chang@lw.com

Latham & Watkins LLP (DC) 555 11th St NW Suite 1000 Washington, DC 20004-1304 202-637-2200 Email: Lawrence.gotts@lw.com

For the Defendants:

RM

DOCKE

Charles Bennett Molster, III, Esq. The Law Offices of Charles B. Molster III, PLLC 2141 Wisconsin Avenue NW, Suite M Washington, DC 20007 703-346-1505 Email: Cmolster@molsterlaw.com

Stephanie Ethel Parker, Esq. Jones Day (GA) 1420 Peachtree Street, NE Suite 800 APPEARANCES: (Cont.)

For the Defendants:

Michael Shamus Quinlan, Esq. Jones Day (OH-NA) 901 Lakeside Avenue Cleveland, OH 44114-1190 216-586-3939 Fax: 216-579-0212 Email: Msquinlan@ionesday.com

Jason Todd Burnette, Esq.

Jones Day (GA) 1420 Peachtree Street, NE Suite 800 Atlanta, GA 30309 404-521-3939 Email: Jburnette@jonesday.com

David Michael Maiorana, Esq.

Jones Day (OH) 901 Lakeside Ave Cleveland, OH 44114 216-586-3939 Email: Dmaiorana@jonesday.com

William Edward Devitt, Esq.

Jones Day (IL) 77 West Wacker Suite 3500 Chicago, IL 60601 312-269-4240 Email: Wdevitt@jonesday.com

Court Reporter:

Scott L. Wallace, RDR, RMR, CRR Official Court Reporter United States District Court 401 Courthouse Square Alexandria, VA 2231-5798 202-277-3739 scottwallace.edva@gmail.com

Proceedings reported by machine shorthand, transcript produced by computer-aided transcription.

Scott L. Wallace, RDR, CRR, Official Court Reporter

432

<u>C O N T E N T S</u>

EXAMINATIONS

CONTINUED DIRECT EXAMINATION OF PAUL MEYER BY MR. SANDFORD	433
CROSS-EXAMINATION OF PAUL MEYER	470
BY MR. McCRUM	
REDIRECT EXAMINATION OF PAUL MEYER	497
BY MR. SANDFORD	
DIRECT EXAMINATION OF JAMES FIGLAR	529
BY MS. PARKER	
CROSS-EXAMINATION OF JAMES FIGLAR	567
BY MR. NAPLES	
REDIRECT EXAMINATION OF JAMES FIGLAR	578
BY MS. PARKER	
RECROSS-EXAMINATION OF JAMES FIGLAR	581
BY MR. NAPLES	

EXHIBITS

DESCRIPTION

<u>Page</u>

Page

Find authenticated court documents without watermarks at docketalarm.com.

	ase	1:20-cv-00393-LMB-TCB Document 140:	-2 1	- lie	d 07/21/22 Page 3 of 4 PageID# 34957
05:39РМ 1	Q.	So not quite 50, you think it's more like 40 trials?	05:41PM	1	MR. NAPLES: Absolutely, Your Honor.
05:39РМ 2	Α.	I think I've given live testimony in court 40 times.	05:41PM	2	THE COURT: All right. Go ahead.
05:39РМ 3	Q.	Okay. And this is actually the first time Ms. Parker	05:41PM	3	BY MR. NAPLES:
05:39PM 4	[sic]	testified here in court; is that right?	05:41PM	4	Q. Now, Dr. Figlar, you talked about these two products, the
05:39PM 5		MS. PARKER: Objection, Your Honor, as to relevance	05:41PM	5	Premier and the Eclipse, correct?
05:39РМ 6	and ·	{indiscernible}.	05:41PM	6	A. Sure, yeah.
05:39РМ 7		THE COURT: Yeah, and you need to slow your questions	05:41PM	7	Q. Okay. And those are not vapor products?
05:40PM 8	dowr	ı.	05:41PM	8	A. They are not vapor products; they are heat-not-burn
05:40PM 9		MR. NAPLES: Sure, Your Honor.	05:41PM	9	products.
05:40PM 10		THE COURT: So everybody gets them. Repeat the question.	05:41PM	10	Q. Okay. And you said those are alternatives to combustible
05:40PM 11	BY M	R. NAPLES:	05:42PM	11	cigarettes, correct?
05:40PM 12	Q.	This is not the first time that Ms. Parker has examined	05:42PM	12	A. They are.
05:40PM 13	you i	n court, correct, Dr. Figlar?	05:42PM	13	Q. All right. Now, Reynolds does not sell the Premier
05:40PM 14		THE COURT: I don't know why that's relevant. I'll	05:42PM	14	product any longer; is that right?
05:40PM 15	susta	in the objection.	05:42PM	15	A. No, they do not.
05:40PM 16		MR. NAPLES: Okay.	05:42PM	16	${\bf Q}.$ Okay. And the Premier was removed from the market, I
05:40PM 17	BY M	R. NAPLES:	05:42PM	17	think you said because people didn't really like the product; is
05:40PM 18	Q.	Now, I think you referred to the cases that you testified	05:42PM	18	that right?
05:40PM 19	in as	smoking and health cases; is that right?	05:42PM	19	A. At that time, that's correct, yes.
05:40PM 20	Α.	That is correct, yes.	05:42PM		Q. Okay. But it was also removed from the market because
05:40PM 21	Q.	Okay. Now	05:42PM	21	there was considerable criticism from the public health
05:40PM 22	Α.	I'm sorry, to be clear, product liability cases.	05:42PM		community; isn't that right?
05:40PM 23	Q.	They're product liability cases?	05:42PM	23	A. The public health community panned the idea of a
05:40PM 24	Α.	I think so, yes.	05:42PM	24	potentially safer product being out on the market, and so there
05:40PM 25	Q.	Okay. Understood. Now, you, I think, said you testified	05:42PM	25	was there was quite a heated debate at that time when Premier
		Scott L. Wallace, RDR, CRR, Official Court Reporter			
		· · · · · ·			Scott L. Wallace, RDR, CRR, Official Court Reporter
05:40PM 1	for R	570	05:42PM	1	572
05:40PM 1		570 eynolds over a period of about ten years in these product	05:42PM	1	572 came out. So, yeah, there were that was part of that was
05:40PM 1 05:40PM 2 05:40PM 3		570 eynolds over a period of about ten years in these product ity cases?	05:42PM 05:42PM 05:42PM	1 2 3	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes.
05:40PM 2	liabil	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes.	05:42PM	2	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was
05:40PM 2 05:40PM 3	liabili A. Q.	570 eynolds over a period of about ten years in these product ity cases?	05:42PM 05:42PM	2 3	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes.
05:40PM 2 05:40PM 3 05:40PM 4	liabili A. Q.	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that	05:42PM 05:42PM 05:42PM	2 3 4	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5	liabili A. Q. that	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that	05:42PM 05:42PM 05:42PM 05:42PM	2 3 4 5	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right?
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6	liabili A. Q. that	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ect?	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM	2 3 4 5 6	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7	liabili A. Q. that	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ect? MS. PARKER: Objection; relevance {indiscernible}.	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:42PM	2 3 4 5 6 7	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8	liabili A. Q. that	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that exct? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this?	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:41PM 9	liabili A. Q. that corre	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ect? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor.	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:41PM 9 05:41PM 10	liabil A. Q. that corre	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 9 05:41PM 10 05:41PM 11	liabil A. Q. that corre	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going.	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it,
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:41PM 9 05:41PM 10 05:41PM 11 05:41PM 12	liabili A. Q. that corre	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ect? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES:	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either.
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 9 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13	liabil A. Q. that corre now. BY M Q. A.	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar?	05:42PM 05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 9 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14	liabil A. Q. that corre Now. BY M Q. A. depo	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct?
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 6 05:40PM 7 05:40PM 8 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15	liabil A. Q. that corre Now. BY M Q. A. depo	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that tect? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse.
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 9 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16	liabil A. Q. that correc Now. BY M Q. A. depo a ye Q.	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. IR. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of ar, yeah.	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 9 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16 05:41PM 17 05:41PM 18 05:41PM 19	now. By M Q. A. depo a ye Q. abou	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of ar, yeah. Okay. Now, you talked during your direct examination	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that Eclipse was initially launched in a small market in 1996?
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 10 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16 05:41PM 17 05:41PM 18 05:41PM 19 05:41PM 20	now. By M Q. A. depo a ye Q. abou	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that heter? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 positions a year, maybe four trials a year over the course of ar, yeah. Okay. Now, you talked during your direct examination t two products, one called the Premier, one called the	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that Eclipse was initially launched in a small market in 1996? A. Yeah, I think it was launched in three small test markets
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 7 05:40PM 8 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16 05:41PM 18 05:41PM 20 05:41PM 20	liabil A. Q. that correc Now. BY M Q. A. depo a ye Q. abou Eclip	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ect? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of ar, yeah. Okay. Now, you talked during your direct examination t two products, one called the Premier, one called the se, right?	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that Eclipse was initially launched in a small market in 1996? A. Yeah, I think it was launched in three small test markets in '96 and then went national in 2000. Q. Okay. And then Reynolds starting started selling the Eclipse nationwide in about 2000?
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 8 05:40PM 8 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16 05:41PM 17 05:41PM 18 05:41PM 20 05:41PM 21 05:41PM 21 05:41PM 21 05:41PM 22	now. BY M Q. A. depo a ye Q. abou Eclip	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that ext? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of ar, yeah. Okay. Now, you talked during your direct examination t two products, one called the Premier, one called the se, right? MS. PARKER: Your Honor, I'm sorry, objection. I want to	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that Eclipse was initially launched in a small market in 1996? A. Yeah, I think it was launched in three small test markets in '96 and then went national in 2000. Q. Okay. And then Reynolds starting started selling the Eclipse nationwide in about 2000? A. Yes, in 2000, that's correct.
05:40PM 2 05:40PM 3 05:40PM 4 05:40PM 5 05:40PM 6 05:40PM 7 05:40PM 7 05:40PM 8 05:41PM 10 05:41PM 11 05:41PM 12 05:41PM 13 05:41PM 14 05:41PM 15 05:41PM 16 05:41PM 18 05:41PM 20 05:41PM 20	liabil A. Q. that correc Now. BY M Q. A. depo a ye Q. abou Eclip: movo we w	570 eynolds over a period of about ten years in these product ity cases? That is correct, yes. Okay. And if you've done about a hundred depositions, is like ten, on average, ten depositions per year; is that het? MS. PARKER: Objection; relevance {indiscernible}. THE COURT: I assume you're going someplace with this? MR. NAPLES: Yes, Your Honor. THE COURT: All right. I'll overrule the objection for Let's see where we're going. R. NAPLES: Is that correct, Dr. Figlar? I mean, that would be probably fair, yeah, about maybe 10 ositions a year, maybe four trials a year over the course of ar, yeah. Okay. Now, you talked during your direct examination t two products, one called the Premier, one called the se, right? MS. PARKER: Your Honor, I'm sorry, objection. I want to a to strike that. We did not go forward as we told Your Honor	05:42PM 05:42PM 05:42PM 05:42PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM 05:43PM	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 920 21 22 23	572 came out. So, yeah, there were that was part of that was definitely part of the controversy, yes. Q. Right. It wasn't just the taste of the Premier, it was also because the public health community criticized Premier; is that right? A. I think there I think it's always in many of these situations, of course it's complicated, but that's one of the factors. The product did not taste that good, for sure, and that is a that is a problem with consumers. But then with the public health community coming out against it, or at least some in the public health community coming out against it, because there were others that were for it, doesn't help either. Q. Right. And then Reynolds removed that product from the market, correct? A. Right, and then started working on Eclipse. Q. Right. And Eclipse, I think well, is it true that Eclipse was initially launched in a small market in 1996? A. Yeah, I think it was launched in three small test markets in '96 and then went national in 2000. Q. Okay. And then Reynolds starting started selling the Eclipse nationwide in about 2000?

	200 1.00 or 00202 LMD 100 Doormoot 100		07/21/22 Dage 4 of 4 Dage D# 24059
	ase 1:20-cv-00393-LMB-TCB Document 140: 573		0 07721722 Page 4 01 4 Page10# 34958 575
05:44PM 1	Q. Okay. And I think the last time we spoke, you told me	05:46РМ 1	Q. I think this is the same slide that Ms. Parker used in
05:44РМ 2	that sales of Eclipse products started declining in 2004 and	05:46РМ 2	her opening, correct?
05:44РМ 3	they've basically been on that trajectory ever since; is that	05:46РМ 3	A. Maybe so. I don't have an eidetic memory in terms of
05:44PM 4	right?	05:46PM 4	what was shown, but, yeah, probably that's fair.
05:44РМ 5	A. Heat-not-burn products have not done well in the U.S.,	05:46РМ 5	Q. Okay. And you testified in your direct examination that
05:44PM 6	that is for sure. And Eclipse, as one of them, has not	05:46РМ 6	the Alto, which is the last product here, that is the
05:44PM 7	performed as well as we would hope or want.	05:46РМ 7	best-selling product or best-selling Vuse product, right?
05:44PM 8	Q. Right. I mean, my question was specifically about the	05:46PM 8	A. Today, yes.
05:44PM 9	Eclipse, okay?	05:46РМ 9	Q. Today, today, correct. Now, it is true, Dr. Figlar, that
05:44PM 10	A. Understood.	05:46PM 10	Reynolds didn't even design the Alto product, right?
05:44PM 11	Q. So the Eclipse's sales have been declining since about	05:46PM 11	A. Alto, no. We were not part of the design. We we
05:44PM 12	2004, correct?	05:47РМ 12	evaluated the product and liked it with one of our suppliers and
05:44PM 13	A. That's fair.	05:47PM 13	licensed it.
05:44PM 14	Q. Okay. And I think you said during your direct	05:47PM 14	Q. Right. A Chinese company called Smoore actually designed
05:44PM 15	examination that Reynolds invested well over a billion dollars	05:47PM 15	the Alto product, right?
05:44PM 16	in the Eclipse and the Premier heat-not-burn products; is that	05:47PM 16	A. Yes, they were one of our suppliers and they offered that
05:44PM 17	right?	05:47PM 17	ир.
05:44PM 18	A. That is correct.	05:47PM 18	Q. And then a different company in China called Feelm, they
05:44PM 19	Q. Okay. And is it true that after spending that billion	05:47PM 19	designed the heater in the Alto product, correct?
05:44PM 20	dollars, Reynolds learned that it was difficult to get consumers	05:47РМ 20	A. I believe that is correct, yes.
05:45PM 21	to convert to heat-not-burn products because they really just	05:47PM 21	Q. Okay. Now, the Vibe product, Reynolds didn't design that
05:45PM 22	couldn't just compete with cigarettes; is that right?	05:47PM 22	product either, did it?
05:45PM 23	A. I think that's generally correct. I mean, Reynolds spent	05:47PM 23	A. Nope, and I don't believe I testified that we did.
05:45PM 24	about 30 years trying to attract consumers to heat-not-burn so I	05:47PM 24	Q. Well, Reynolds didn't design the Ciro product either; is
05:45PM 25	think that's a fair statement.	05:47PM 25	that right?
	Scott L. Wallace, RDR, CRR, Official Court Reporter		Scott L. Wallace, RDR, CRR, Official Court Reporter
	574		576
05:45PM 1	Q. Okay. So let's move ahead. So we've got the Premier off	05:47РМ 1	A. That's correct. I'm pretty sure that's what I told the
05:45РМ 2	the market, Eclipse isn't selling well, we're going to be in the	05:47РМ 2	· · · · · ·
05:45PM 3	2010 time frame, and I think that's when you said that Reynolds		jury.
A		05:47РМ З	Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe,
05:45PM 4	started to get into the e-vapor or e-cigarette space; is that	05:47РМ З 05:47РМ 4	
05:45PM 4 05:45PM 5	started to get into the e-vapor or e-cigarette space; is that right?		Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe,
_		05:47PM 4	Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that
05:45PM 5	right?	05:47РМ 4 05:47РМ 5	Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct?
05:45PM 5 05:45PM 6	right? A. When we started to seriously start thinking about	05:47PM 4 05:47PM 5 05:47PM 6	 Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant.
05:45PM 5 05:45PM 6 05:45PM 7	right? A. When we started to seriously start thinking about developing products, yes.	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 9	 Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me?
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8	right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11	right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements?	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 9 05:48PM 10 05:48PM 11	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection.
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12	right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes.	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor.
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES:
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16 05:46PM 17	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16 05:46PM 18	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17 05:48PM 18	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16 05:45PM 18 05:46PM 19	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. MR. NAPLES: Could I have your Slide 3 up? 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 10 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17 05:48PM 18 05:48PM 19	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of them, correct?
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16 05:46PM 17 05:46PM 18 05:46PM 19 05:46PM 20	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. MR. NAPLES: Could I have your Slide 3 up? 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 16 05:48PM 18 05:48PM 19 05:48PM 20	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of them, correct?
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 16 05:46PM 17 05:46PM 18 05:46PM 20 05:46PM 20	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. MR. NAPLES: Could I have your Slide 3 up? BY MR. NAPLES: Q. You showed this slide to the jury I believe; is that 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17 05:48PM 18 05:48PM 19 05:48PM 20 05:48PM 21	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of them, correct? A. That is correct, but what we certainly did do is support them in the marketplace and then collected the science that
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 15 05:45PM 16 05:46PM 16 05:46PM 18 05:46PM 19 05:46PM 20 05:46PM 21 05:46PM 22	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. MR. NAPLES: Could I have your Slide 3 up? BY MR. NAPLES: Q. You showed this slide to the jury I believe; is that right 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 10 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17 05:48PM 18 05:48PM 20 05:48PM 21 05:48PM 21 05:48PM 22	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of them, correct? A. That is correct, but what we certainly did do is support them in the marketplace and then collected the science that would be necessary to keep them in the U.S. market through FDA,
05:45PM 5 05:45PM 6 05:45PM 7 05:45PM 8 05:45PM 9 05:45PM 10 05:45PM 11 05:45PM 12 05:45PM 13 05:45PM 14 05:45PM 16 05:46PM 17 05:46PM 18 05:46PM 20 05:46PM 20 05:46PM 20 05:46PM 21	 right? A. When we started to seriously start thinking about developing products, yes. Q. Okay. And you also were here for Ms. Parker's opening statements? A. I was, yes. Q. And she talked about how Reynolds is actually an innovator in that space, right? A. Yeah, I believe, absolutely. Q. She actually said that you were going to talk about how they were an innovator in that space; is that right? A. I thought I did when I talked about some of the innovative features on Solo, which is part of that development. Q. Sure. Let's discuss that a little bit. MR. NAPLES: Could I have your Slide 3 up? BY MR. NAPLES: Q. You showed this slide to the jury I believe; is that 	05:47PM 4 05:47PM 5 05:47PM 6 05:47PM 7 05:47PM 8 05:47PM 8 05:47PM 8 05:47PM 8 05:48PM 9 05:48PM 10 05:48PM 11 05:48PM 12 05:48PM 12 05:48PM 13 05:48PM 14 05:48PM 15 05:48PM 16 05:48PM 17 05:48PM 18 05:48PM 19 05:48PM 20 05:48PM 21	 Q. Right, Reynolds, in fact, acquired the Ciro, the Vibe, and the Alto products from Chinese manufacturers; is that correct? MS. PARKER: Objection, Your Honor, 403, irrelevant. THE COURT: Excuse me? MS. PARKER: 403 irrelevance on the location THE COURT: I'm going to overrule the objection. MR. NAPLES: Thank you, Your Honor. MS. PARKER: Your Honor, I'm so sorry. The pretrial ruling on that THE COURT: It's getting late in the day. You've got your mask on, you're not at the lectern, and I've overruled the objection. Just have a seat, please. BY MR. NAPLES: Q. So, Dr. Figlar, it's true that of the four vapor platforms that Reynolds sells today, it didn't design three of them, correct? A. That is correct, but what we certainly did do is support them in the marketplace and then collected the science that